ClinicalTrials.gg
RecruitingNCT06302062TAL-TUpdated Dec 3, 2024

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

A Phase 1 interventional study of Tumor Associated Lymph node T cell and cyclophosphamide in Advanced Solid Tumor, Tumor Associated Lymph Node T Cell and Immunotherapy, sponsored by Guangzhou FineImmune Biotechnology Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Guangzhou FineImmune Biotechnology Co., LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jun 2023, registered Mar 2024).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · China.

Planned enrollment
24th of 33
23 · median 44
Started
2023
with 5 others
Phase 1
6 of 53
5 open now
Primary completion
2025-12
later than 5 of 14 live
Registered
44th of 53
by date
Lead sponsor
2 of 53
Guangzhou FineImmune Biotechnology Co., LTD.

Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, this one is the 24th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is one of 6 in phase 1, reaches primary completion later than 5 of the 14 other live ones, and was the 44th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

14 of the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 37 (67%) set no upper age limit and 15 (27%) stop at 75 or younger; 14 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, or all of them as a file.
02

Study summary

A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection.

To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.

Read the detailed description

This is an open, single-center Phase I clinical trial designed to assess the safety, tolerability, efficacy, and feasibility of tumor-associated lymph node T cells (TAL-T) for treating metastatic solid tumors. The study consists of three distinct phases: screening, administration of treatment, and follow-up evaluation. In this investigation, TAL-T cells will be cultured after being separated in a laboratory setting. Participants will receive 1-2 infusions of TAL-T cells.

03

Conditions studied

  • Advanced Solid Tumor
  • Tumor Associated Lymph Node T Cell
  • Immunotherapy

Keywords

  • TAL-T
  • cell therapy
  • Tumor Associated Lymph node T cell
  • Safety
  • Adverse Drug Event
  • Efficacy
  • Immunotherapy
  • Serplulimab Injection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Before conducting tumor-associated lymph node sampling, it is necessary to verify that subjects meet the inclusion criteria marked with an asterisk (*). These criteria include:

  1. * being between the ages of 18 and 75;
  2. having or locally advanced /recurrent malignant solid tumors that have failed standard therapy or have failed to tolerate standard treatment;
  3. having at least one measurable target lesion;
  4. * voluntarily participating and signing an form;
  5. * having at least one resectable tumor-associated lymph node from which T cells can be successfully isolated;
  6. * having an score of 0-1;
  7. * having an expected survival of more than 6 months;
  8. * female subjects with fertility potential must have a negative pregnancy test, and all men and women with fertility potential must consent to using medically effective during the study period and for 12 months after the last dose of the study medication;
  9. * being willing to regularly come to the hospital for treatment, testing, evaluation, and management as required during the entire study period.

Before sampling tumor-associated lymph nodes, it is important to confirm that the subject does not meet any of the exclusion criteria marked with an asterisk (*). These criteria include:

  1. * Experiencing moderate to severe infection or at risk of opportunistic infection;
  2. * Present with active disease (other than vitiligo or childhood asthma/allergies that have healed);
  3. * Uncontrolled concomitant disease, including but not limited to symptomatic congestive heart failure, unstable angina pectoris, arrhythmias (excluding stable atrial fibrillation), and significant carotid stenosis.
  4. * Acute systemic infections, coagulation disorders or other serious cardiopulmonary diseases;
  5. Patients who have used large amounts of or other within 4 weeks;
  6. * A history of severe to any of the drugs used in this study;
  7. Known uncontrolled central nervous system (CNS) metastases and/or cancerous meningitis;
  8. * Pregnant and lactating women, as well as women and men who were unable to cooperate with contraception during the study period;
  9. Previous anti-tumor therapy: within four weeks of radiotherapy, chemotherapy, one week after TKI inhibitor treatment, four weeks of therapy or four half-lives, whichever is shorter;
  10. * Enroll in another clinical study at the same time, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study;
  11. * Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation;
  12. * Known history of interstitial lung disease. Exclude subjects with high suspicion of interstitial pneumonia; Or may interfere with the detection or management of suspected drug-related pulmonary toxicity; Or other moderate to severe lung diseases that seriously affect lung function;
  13. * Known history of primary immunodeficiency virus infection or positive test;
  14. * Patients with chronic or HBV carriers of chronic hepatitis B virus (HBV), or patients with active should be excluded;
  15. * Any of the following cardiovascular diseases

    1. have evidence of acute or persistent episodes of myocardial ischemia;
    2. symptomatic pulmonary embolism is present;
    3. acute myocardial infarction occurred within 6 months prior to the initial study treatment;
    4. symptomatic congestive heart failure (grade 3 or 4 according to the Functional Scale) occurred within 6 months prior to the first study treatment;
    5. Occurrence of grade 2 or more ventricular arrhythmias within 6 months prior to the first study treatment;
    6. cerebrovascular accident or transient ischemic stroke occurred within 6 months prior to the first study treatment
  16. * Subjects with pleural effusion, pericardial effusion, or ascites that, in the investigator\'s judgment, cannot be stably controlled by repeated drainage or other methods;
  17. Have received a within 30 days prior to the first dose or plan to receive a live vaccine during the study period;
  18. * Disease known to produce severe hypersensitivity to other monoclonal antibodies;
  19. Any condition that the investigator believes may result in a risk of acceptance of the study drug treatment or interfere with the evaluation of the study drug or the safety of the subjects or the interpretation of the study results;
  20. * With a second primary tumor (within 5 years).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    Cohort A

    Three patients were planned to be enrolled, and each subject received one to two cell transfusions.

    Drug: Tumor Associated Lymph node T cell · Drug: cyclophosphamide · Drug: IL-2

  • Experimental
    Cohort B

    14 to 20 patients were enrolled, and each subject received one to two cell transfusions. In this group, Tumor Associated Lymph node T cells were combined with Serplulimab Injection.

    Drug: Tumor Associated Lymph node T cell · Drug: cyclophosphamide · Drug: IL-2 · Drug: Serplulimab Injection

Interventions

  • DrugTumor Associated Lymph node T cell

    At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.

    Also known as: TAL-T cells, TAL-T

  • A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.

  • DrugIL-2

    The IL-2 treatment will be continued for 5 days.

    Also known as: Cellular interleukin 2, interleukin-2

  • In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .

    Also known as: PD1 monoclonal antibody, PD1

06

What researchers measure

Primary outcomes

  1. DLT

    The dosage of TAL-T was determined to limit toxicity

    Time frame: At least 58 days

  2. MDT

    Determine the maximum tolerated dose of TAL-T

    Time frame: At least 58 days

  3. Number of participants with treatment-related adverse events as assessed by CTCAE V4.03

    Keep record the adverse eventd experienced by subjects in 30 days after the last infusion

    Time frame: At least 60 days

Secondary outcomes

  1. ORR

    The proportion of subjects receiving a confirmed optimal response of PR or above which was evaluation according to RECIST or iRECIST principles.

    Time frame: one yaer

  2. PFS

    The time between the subject receiving treatment and the onset of PD or death from any cause, whichever occurs first. If the subject had no events (PD or death), the last response assessment day was the cut-off time for PFS.

    Time frame: two years

  3. life quality score

    ECOG 0-1

    Time frame: At least 70 days

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Gaungdong 510700, China
    Recruiting
    • Xiaoshi Zhang · Contact020-8734-3383
    • Xiaoshi Zhang, professor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Dec 2025, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 8, 2024
StartActual
Jun 6, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06302062
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Jun 6, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 3, 2024

Study contacts

Ying Cheng, Master
Contact
chengy02@fineimmu.com
86-020-31605836

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion